Repligen | RGEN - Frais De Vente Et D'Administration





Frais De Vente Et D'Administration Changement Date
Agilent USD 476M 48M 2025-12
Align Technology USD 465.34M 23.67M 2026-03
Bio Techne USD 109.34M 4.35M 2026-03
BioMarin Pharmaceutical USD 258.28M 63.92M 2026-03
Bristol-Myers Squibb USD 1.62B 564M 2026-03
Bruker USD 242.1M 5.1M 2026-03
Charles River Laboratories USD 159.42M 36.71M 2026-03
Danaher USD 1.86B 166M 2026-03
Dentsply International USD 351M 32M 2026-03
General Electric Aerospace USD 1.08B 496M 2026-03
Henry Schein USD 809M 1000K 2026-03
Illumina USD 272M 11M 2026-03
IQVIA Holdings USD 502M 34M 2026-03
Mettler Toledo International USD 258.33M 1.5M 2026-03
Myriad Genetics USD 122.3M 6.7M 2025-12
OraSure Technologies USD 13.21M 3.29M 2025-12
Pacific Biosciences Of California USD 37.24M 25.68M 2025-12
Pfizer USD 2.92B 1.16B 2026-03
Repligen USD 76.54M 2.17M 2026-03
Revvity USD 253.88M 2.15M 2026-03
Standard Biotools USD 21.55M 5.05M 2025-12
Thermo Fisher Scientific USD 1.8B 179M 2026-03
Waters USD 394M 153.99M 2026-03
West Pharmaceutical Services USD 99.5M 7M 2026-03